Argenx Se (ARGX) Other Non-Current Liabilities (2016 - 2017)
Argenx Se (ARGX) posted quarterly Other Non-Current Liabilities of $18.9 million for Q2 2017, up 7.18% on a QoQ basis from $17.6 million in Q4 2016.
Argenx Se (ARGX) Other Non-Current Liabilities (2016 - 2017) Analysis & Trends
Argenx Se (ARGX) has reported Other Non-Current Liabilities for 2 consecutive years, with $18.9 million the latest figure, recorded in Q2 2017.
- Quarterly Other Non-Current Liabilities changed N/A year-over-year to $18.9 million in Q2 2017, while the trailing twelve-month figure through Jun 2017 was $18.9 million (changed N/A YoY) and the FY2016 annual result came in at $17.6 million, changed N/A from the prior year.
- Other Non-Current Liabilities improved to $18.9 million in Q2 2017 per ARGX's latest filing, from $17.6 million in the prior quarter.
- Over the last five years, Other Non-Current Liabilities for ARGX reached as high as $18.9 million in Q2 2017 and fell as low as $17.6 million in Q4 2016.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Alnylam Pharmaceuticals | 35.71 Bn | 32.70 Bn | 959.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2017 | 18.86 Mn |
| Dec 31, 2016 | 17.60 Mn |